The pooled results involving 82,654 patients demonstrated that SGLT2 inhibitor use was associated with a significant 54% reduction in the risk of all-cause mortality (RR 0.46, 95% CI 0.31–0.68, P < 0.0001) and a 51% reduction in heart failure hospitalization (RR 0.49, 95% CI 0.30–0.81, P = 0.006) compared to patients not receiving SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is heart failure.